Investing

Ardelyx : ARDX

ARDX

Stock Data

$6.88

$0.55 (8.69%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Ardelyx Inc is a biopharmaceutical company focused on developing innovative treatments for gastrointestinal and cardiorenal diseases. Its flagship product, tenapanor, aims to alleviate symptoms of irritable bowel syndrome with constipation. Additionally, Ardelyx is advancing treatments for chronic kidney disease and related conditions, including a therapy to manage serum phosphorus levels and another targeting elevated serum potassium. With partnerships in various territories, Ardelyx is committed to addressing significant unmet medical needs. Founded in 2007 and based in Waltham, Massachusetts, the company continues to expand its therapeutic portfolio.

All Ardelyx Articles

3 Articles

Lee Jackson | Jan 3, 2023 at 8:45 AM EST

Tuesday’s Top Analyst Upgrades and Downgrades: Ally Financial, Apple, Block, DR Horton, EOG, Ford, Micron, PayPal, Pfizer and More

Tuesday's top analyst upgrades and downgrades included Ally Financial, Apple, Ardelyx, Block, DocuSign, D.R. Horton, Enovix, EOG Resources, Ford, Futu,…

Chris Lange | May 6, 2022 at 10:50 AM EDT

April’s Tight Labor Market Numbers: Analysts Upgrade or Downgrade Coupang, Hanesbrands, United Airlines and More

Friday’s additional top analyst upgrades and downgrades were on Amarin, Ardely, Ball, Coupang, Hanesbrands, United Airlines, Vimeo and more.

Chris Lange | Jul 20, 2021 at 12:32 PM EDT

Apple, Array Tech, Vertex Pharma and More Tuesday Afternoon Analyst Calls

24/7 Wall St. looks at some big analyst calls that we have seen so far on Tuesday, including Apple, Array…